SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-20-303749
Filing Date
2020-11-25
Accepted
2020-11-25 17:21:20
Documents
70
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q d96959d10q.htm 10-Q 1161023
2 EX-31.1 d96959dex311.htm EX-31.1 10612
3 EX-31.2 d96959dex312.htm EX-31.2 10624
4 EX-32.1 d96959dex321.htm EX-32.1 4111
5 EX-32.2 d96959dex322.htm EX-32.2 4119
  Complete submission text file 0001193125-20-303749.txt   6380784

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT algs-20201031.xml EX-101.INS 1420605
7 XBRL TAXONOMY EXTENSION SCHEMA algs-20201031.xsd EX-101.SCH 54866
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE algs-20201031_cal.xml EX-101.CAL 43494
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE algs-20201031_def.xml EX-101.DEF 262511
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE algs-20201031_lab.xml EX-101.LAB 451250
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE algs-20201031_pre.xml EX-101.PRE 380782
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39617 | Film No.: 201351989
SIC: 2836 Biological Products, (No Diagnostic Substances)